BioSante Bio-E-Gel Phase III data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
BioSante plans an NDA submission for its transdermal estradiol gel Bio-E-Gel "as soon as possible" following positive results from a Phase III trial in menopausal women. The 12-week, 484-patient study looked at three dose levels. Beginning at week five, highly significant decreases in the number (p<0.001) and severity (p<0.01) of hot flashes compared to placebo were observed with the lowest study dose. "We believe the low dose…will be an attractive alternative to currently marketed estrogen therapies," BioSante says. The company is aiming at the market created largely by Solvay's EstroGel. BioSante also hopes to tap into the female sexual dysfunction market with its testosterone gel LibiGel. A Phase III study in FSD is slated to begin by year-end (1Pharmaceutical Approvals Monthly April 2005, p. 5)...
You may also be interested in...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.